文献速递肺外科

全国范围内机器人肺叶切除术治疗非小细胞肺癌的评估

Nationwide Assessment of Robotic Lobectomy for Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2017-01-18

该研究基于美国国家癌症数据库(2010-2012年)I-IIIA期NSCLC患者,分析机器人肺叶切除术的使用趋势、相关因素及结局。机器人肺叶切除术从3.0%增至9.1%(p<0.001),学术中心和高容量医院更常使用。与开胸相比住院时间更短(6.1 vs 6.9天;p<0.001),但与胸腔镜相比淋巴结检出数较少(9.9 vs 10.9;p<0.001),切缘阳性、再入院及30/90天死亡率无差异。

要点

  • 机器人肺叶切除术在I-IIIA期NSCLC中应用显著增加,2010至2012年从3.0%升至9.1%。
  • 学术中心和高容量医院更倾向于使用机器人肺叶切除术。
  • 机器人术后住院时间短于开胸,但淋巴结检出数少于胸腔镜,短期安全性结局相似。

核心结论

  • 机器人肺叶切除术在I-IIIA期NSCLC患者中显著增加,结局与其他入路相似。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2010至2012年I-IIIA期NSCLC患者数据。
  • 共62,206例肺叶切除术患者,其中开胸45,527例、胸腔镜12,990例、机器人3,689例,来自1,215家医院。
  • 采用多变量logistic回归分析机器人手术使用相关因素,并构建倾向性匹配队列比较术后结局。

主要发现

  • 机器人肺叶切除术占比从2010年3.0%增至2012年9.1%(p<0.001)。
  • 学术医院(OR 1.55;95%CI 1.04-2.33)和高容量医院(OR 1.49;95%CI 1.04-2.14)与机器人肺叶切除术使用增加相关。
  • 机器人 vs 开胸:住院时间更短(6.1 vs 6.9天;p<0.001)。
  • 机器人 vs 胸腔镜:淋巴结检出数更少(9.9 vs 10.9;p<0.001),检出≥12枚淋巴结的比例更低(32.0% vs 35.6%;p=0.005)。
  • 机器人 vs 开胸或胸腔镜:切缘阳性、30天再入院、30天和90天死亡率均无差异。

临床怎么用

  • 机器人肺叶切除术可作为I-IIIA期NSCLC的可行选择,短期结局与开胸和胸腔镜相似。
  • 需关注机器人手术淋巴结清扫可能不充分,应规范淋巴结采样或清扫。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robotic lobectomy has been described for non-small cell lung cancer (NSCLC). Our objectives were to (1) evaluate the use of robotic lobectomy over time, (2) identify factors associated with its use, and (3) assess outcomes after robotic lobectomy compared with other surgical approaches. METHODS: Stage I to IIIA NSCLC patients were identified from the National Cancer Data Base (2010 to 2012). Trends in robotic lobectomy were assessed over time, and multivariable logistic regression models were developed to identify factors associated with its use. Propensity-matched cohorts were constructed to compare postoperative outcomes after robotic lobectomy with thoracoscopic and open lobectomy. RESULTS: Lobectomy was performed in 62,206 patients by open (n = 45,527), thoracoscopic (n = 12,990), or robotic (n = 3,689) procedures at 1,215 hospitals. Between 2010 and 2012, robotic lobectomy significantly increased, from 3.0% to 9.1% (p < 0.001). Academic (odds ratio, 1.55; 95% confidence interval, 1.04 to 2.33) and high-volume hospitals (odds ratio, 1.49; 95% confidence interval, 1.04 to 2.14) were associated with increased use of robotic lobectomy. Length of stay was shorter in robotic lobectomy compared with open lobectomy (6.1 vs 6.9 days; p < 0.001). Fewer lymph nodes (9.9 vs 10.9; p < 0.001) and 12 or more nodes were examined less frequently (32.0% vs 35.6%; p = 0.005) in robotic resections than in thoracoscopic resections. There was no difference between robotic and open or robotic and thoracoscopic lobectomy patients in margin positivity, 30-day readmission, and deaths at 30 and 90 days. CONCLUSIONS: Robotic lobectomies have significantly increased in stage I to IIIA NSCLC patients, with outcomes similar to other approaches. Additional studies are needed to determine if this technology offers potential advantages compared with video-assisted thoracoscopic operations.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Rajaram R, Mohanty S, Bentrem DJ, et al. Nationwide Assessment of Robotic Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017. PMID: 28109575. doi:10.1016/j.athoracsur.2016.09.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。